Legal entity

Mereo BioPharma Group plc

Company MREO

Last mentioned: Mar 5, 2026

Entity pulse

Recent coverage · Mereo BioPharma Group plc

1 story
5 avg impact
0% positive
0% negative
  • 100% neutral

Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.

What the coverage shows about Mereo BioPharma Group plc

Every one of those 1 sits in a single category, corporate-law. Of the tracked stories, 1 of 1 also mention Fermi Inc, the most common co-covered peer. They are better corroborated than the beat average, carrying 4 original sources each against 2.8 for the same window. The 5 average consequence score is below the beat benchmark of 6.4 in the same window. We currently track 1 Legal story that mention Mereo BioPharma Group plc, all published on March 5, 2026.

Stories tracked
1
Sources per story
4

Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 56 Legal stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.

Coverage cohort

Appears alongside

Other entities that clear the same relevance threshold in stories also covering Mereo BioPharma Group plc. Shared-story counts are live from our verified record — not editorial picks.

Timeline

  1. Lead Plaintiff Deadline

    Estimated deadline for investors to file motions to be appointed as lead plaintiff in the respective cases.

  2. Market Reaction

    Investors and analysts begin assessing the potential litigation overhang on RARE, MREO, FRMI, and NAVN.

  3. Investor Alerts Issued

    Pomerantz Law Firm releases simultaneous reminders for class action lawsuits against four companies.

Stories mentioning Mereo BioPharma Group plc 1

Corporate Law Neutral

Pomerantz Law Firm Targets Biotech and Tech Sectors in Securities Class Actions

Pomerantz Law Firm has issued a series of investor alerts regarding class action lawsuits against Ultragenyx Pharmaceutical, Fermi Inc., Mereo BioPharma, and Navan, Inc. These filings highlight a surge in securities litigation targeting volatility in the biotechnology and emerging technology sectors, emphasizing critical lead plaintiff deadlines for affected shareholders.

4 sources

Source: prnewswire.com · prnewswire.com

Mereo BioPharma Group plc is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.

See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.